For example, the SELECT trial clearly demonstrated that semaglutide significantly reduces the risk of major adverse cardiovascular events (MACE), leading to FDA approval for lowering the risk of cardiovascular death, myocardial infarction, or stroke in overweight or obese adults with established cardiovascular disease (Marso et al., 2016a)
Adv Gerontol Uspekhi Gerontol 2021;34:107
Tirzepatide (Mounjaro) is a highly effective weight loss treatment for individuals with a body mass index (BMI) of 30 or above, or those with a BMI of 27 or higher who also have conditions like type 2 diabetes, high blood pressure, or elevated cholesterol levels
Effect of simultaneous testing of two mice in the tail suspension test and forced swim test
We often encourage our patients to choose where they would like to administer their semaglutide but rotate between locations often to avoid complications